Provectus Biopharmaceuticals

Provectus Biopharmaceuticals

Provectus Biopharmaceuticals was incorporated in 2002 and went public via a reverse merger in 2006, establishing operations in Knoxville, Tennessee. The firm's identity is inseparable from Rose Bengal sodium, a halogenated fluorescein derivative it reformulated as PV-10 — an intralesional immunotherapy for solid tumors. Founders Eric Wachter and Dominic Rodrigues built the company around this single molecule, patenting its use across oncology indications including melanoma, hepatocellular carcinoma, and neuroblastoma. The company's strategy has been unusually narrow: advance PV-10 through investigator-initiated trials and a single pivotal Phase 3 study for locally advanced melanoma, while licensing veterinary and cosmetic uses of Rose Bengal to generate nominal revenue. Provectus never built an internal sales force, never in-licensed external assets, and never broadened into a multi-candidate pipeline — making it structurally closer to a special-purpose acquisition company than a traditional biotech. Geographic reach extended to Australia, where the pivotal melanoma trial enrolled patients, and to Chinese licensing discussions that repeatedly surfaced in corporate presentations between 2015 and 2020. As of its last comprehensive SEC filing, headcount has rarely exceeded a dozen full-time employees, with outsourced CROs and academic collaborators carrying the clinical load. The firm's adjacent vehicle, Provectus Pharmaceuticals Pty Ltd, a dormant Australian subsidiary, once held regional intellectual property. In February 2024, the company's OTC-traded stock was suspended by the SEC due to delinquent filings, and in April 2024, it withdrew its long-stalled Phase 3 melanoma application with the FDA — effectively ending its prospects as a going concern. Provectus's structural differentiator was not scientific but financial: it sustained a 20-year clinical program almost entirely through equity-dilutive financing, eschewing pharmaceutical partnerships that would have diluted its intellectual property control. That posture — a publicly traded, single-molecule holding company — is virtually extinct in modern biotech, where portfolio diversification and early-exit licensing dominate.